A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer

This study evaluated the efficacy and safety of durvalumab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for 40 patients with resectable stage III Non-small Cell Lung Cancer (NSCLC). The treatment achieved a 65% Objective Response Rate (ORR), with 67.5% of patients achieving Major Pathological Response (MPR) and 22.5% achieving Complete Pathological Response (pCR). The expression of PD-1 on T lymphocytes significantly decreased post-treatment, indicating improved immune function. Common adverse events included hair loss (47.5%), nausea and vomiting (42.5%), and fatigue (40%), mostly grades 1 and 2. The average Disease-Free Survival (DFS) was 21.49 months, and Overall Survival (OS) was 24.79 months. The treatment showed a high pathological response rate and good tolerability, suggesting potential for extending patient survival.